Crowdfunder for a new weekly anti-hormonal contraceptive!
Here is our plan.
Mifepristone (the active ingredient of the abortion pill) in a small doses can be used as a weekly on-demand contraceptive. We are now starting a large clinical trial to confirm its efficacy and safety. After the trial, Mifepristone can be registered and distributed as a contraceptive. You could then use Mifepristone once a week to avoid getting pregnant. It also works as a morning-after pill. In this way you can use it on demand.
Current oral contraceptive options do not respond to everybody’s needs, and are not necessarily the right method for every woman. Despite important progress in the development of new contraceptive methods, a significant share of women of reproductive age that want to stop or delay childbearing, are not using a method of contraception. Globally, nearly half of all pregnancies (121 million each year) are unintended (UNFPA, 2022)
Mifepristone, is an anti-progesterone is an extremely effective morning-after pill and holds great promise as a weekly on-demand contraceptive. And it does not have the side effects of existing contraception (OC). Widely available and proven safe, Mifepristone can fundamentally change the way women all over the world will be able to control their fertility.
It would allow us to move flexibly between the medicine’s different indications as weekly contraceptive, as an on-demand method used before or after sexual intercourse, depending on our life circumstances.
Smaller clinical trials have confirmed that Mifepristone is safe and works as a contraceptive. But we need more extensive studies to get the drug approved and clinically implemented. So that is why Women on Waves is setting up the required clinical trial at the moment, which could change the reproductive landscape for women across the world.
An international experienced medical, scientific and ethics team has been convened by Women on Waves to conduct these larger clinical trials in keeping with the requirements of theFDA and European Medicine Agency (EMA), which has advised on this project. After completing the study with success, other international organisations have committed to making Mifepristone available around the world. Seven hospitals have joined the trial and we have all clinical and ethical approvals in place to get started.
We will conduct a study with 949 women using 50 mg of Mifepristone weekly for a year, in order to provide the data needed to request the registration as a weekly contraceptive to the EMA.
If you would like to get the full study protocol and study approvals, email us: email@example.com
If you need abortion pills now please go to www.aidaccess.org